0000000000803122

AUTHOR

Pascal Guerard

showing 2 related works from this author

Arachidonic acid relaxes human pulmonary arteries through K+ channels and nitric oxide pathways.

2004

We aimed to investigate the role of K(+) channels and nitric oxide (NO) on the relaxant effects of arachidonic acid in the human intralobar pulmonary arteries. Arachidonic acid produced a concentration-dependent relaxation (E(max)=93+/-3% of maximal relaxation induced by papaverine 0.1 mM;-log EC(30)=7.03+/-0.09) that was antagonized by the cyclooxygenase inhibitor indomethacin (1 microM), by the combination of cyclooxygenase blockade and cytochrome P450 (CYP) blockade with 17-octadecynoic acid (17-ODYA, 10 microM), by the combination of cyclooxygenase inhibition and NO synthase (NOS) inhibition with N(omega)-nitro-l-arginine (l-NOARG, 100 microM), by the simultaneous inhibition of CYP and …

PharmacologyArachidonic AcidPotassium ChannelsCharybdotoxinDose-Response Relationship DrugStereochemistryPharmacologyIn Vitro TechniquesPulmonary ArteryApaminNitric OxidePotassium channelNitric oxideGlibenclamideVasodilationchemistry.chemical_compoundchemistrymedicineHumansArachidonic acidChannel blockerUnsaturated fatty acidmedicine.drugSignal TransductionEuropean journal of pharmacology
researchProduct

Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report

2020

Background We report here a case where no everolimus pleural diffusion was evidenced at the same time of pleural progression of a metastatic breast cancer treated with everolimus and exemestane. Case description A 69-year-old woman was diagnosed in October 2006 with stage III invasive ductal breast adenocarcinoma. After nine months of everolimus and exemestane treatment, she presented with a pleural progression. Everolimus concentration was measured in blood and in pleural fluid. Residual blood concentration was at 9.1 ng/mL, while no everolimus was observed in the pleural fluid. Management and outcome Due to inefficacy of everolimus in this patient, she was switched to palbociclib and fulv…

Oncologymedicine.medical_specialtyPyridinesBreast NeoplasmsPiperazines03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)EverolimusAgedEverolimusbusiness.industrymedicine.diseaseMetastatic breast cancerAndrostadienesOncology030220 oncology & carcinogenesisDisease ProgressionPleural fluidFemalebusiness030215 immunologymedicine.drugJournal of Oncology Pharmacy Practice
researchProduct